Laevoroc Oncology

Executive Summary

Laevoroc Oncology AG is a Swiss biopharmaceutical company founded in 2019, dedicated to developing next-generation cancer immunotherapies for hematological malignancies and other cancers. The company leverages state-of-the-art technology and deep oncology expertise to address significant unmet medical needs. Although still in early stages with no disclosed pipeline or funding details, Laevoroc's focus on innovative small molecule immunotherapies positions it in a competitive but promising space. The company's progress is closely tied to upcoming preclinical and clinical milestones.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program60% success
• Q3 2026Presentation of Preclinical Data at Major Conference75% success
• Q2 2026Series A Financing Announcement50% success